Clinical Trials in North Carolina

Showing 12461-12480 of 20,428 trials

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

NCT02840994

The objective of the proposed clinical trial is to investigate the safety and tolerability of CV301 in combination with Anti-PD1-Therapy in subjects with non-small cell lung cancer (NSCLC). The clinical trial is designed to evaluate the possible enhanced antitumor activity of CV301 with Anti-PD1-Therapy. The rationale for combining CV301 with Anti-PD1-Therapy is based on the hypothesis that CV301 can induce specific immune response in the tumor, and that in combination, Anti-PD1-Therapy may augment the T cell-mediated immune response generated by CV301 by blocking the inhibitory signal of the PD-1. The trial will include a Phase 1 portion and a Phase 1b portion with 2 cohorts. The Phase 1 portion is a dose escalation part to assess the safety and tolerability of CV301 alone, prior to moving into the combination with Anti-PD1-Therapy (the Phase 1b component). The following Phase 1b portion of the trial aims to test the safety and tolerability of the combination treatment using a two cohort approach with cohort 1 receiving CV301 plus Nivolumab and cohort 2 receiving CV301 plus Pembrolizumab.

Non-small Cell Lung Cancer (NSCLC)

Bavarian Nordic24 participantsStarted Dec 2016

Tampa, Florida, United States • Indianapolis, Indiana, United States • Metairie, Louisiana, United States +4 more locations

COMPLETEDPhase 346 miles

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

NCT03021187

This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 Diabetes Mellitus treated with insulin. All subjects should continue their pre-trial insulin therapy (basal, basal-bolus or premixed regimen including combinations of soluble insulins) throughout the trial. Subjects treated with metformin in addition to insulin treatment must continue their metformin treatment throughout the entire trial.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S731 participantsStarted Feb 2017

Anniston, Alabama, United States • Birmingham, Alabama, United States • Fountain Hills, Arizona, United States +115 more locations

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Find Trials by Condition in North Carolina

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

Pregnancy Eating Attributes Study

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors

Asthma L-Citrulline Pilot Study

Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

Patient and Provider Assessment of Lipid Management Registry

Telerehabilitation in the Home Versus Therapy In-Clinic for Patients With Stroke

Intrathecal Mafosfamide

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Valacyclovir in Immunocompromised Children

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

Assistive ExoSkeletons to Enable Wearable Rehabilitation Robotics